| Term 
 
        | Which non-opioid analgesic is used to treat OA? |  | Definition 
 
        | Tylenol/Acetaminophen Site of action: CNS. Inhibits COX only there
 |  | 
        |  | 
        
        | Term 
 
        | Why doesn't Tylenol work at the site of inflammation? |  | Definition 
 
        | Tylenol is inhibited by peroxides, no peroxides in the CNS. Inhibits fever due to CNS action
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | The amount it takes to inhibit to 50%. A lower number is more potent. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | The highly reactive intermediate of tylenol found in the liver. Tied up by glutathione. If glutathione cannot process all of the NAPQI --> Liver toxicity |  | 
        |  | 
        
        | Term 
 
        | What drug can be used to treat APAP toxicity? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are the classifications of COX inhibitors? |  | Definition 
 
        | - COX1 selective - Cox1 inhibitor with no activity on Cox2 - COX nonselective - Can inhibit both by fitting into both enzymes
 - COX 2 Preferential - Affects COX2 more than Cox1, but will inhibit Cox1 in higher doses
 - Cox-2 selective - Only inhibits Cox2 at maximum doses.
 |  | 
        |  | 
        
        | Term 
 
        | Why were Cox2 inhibitors developed? |  | Definition 
 
        | - Anti-inflammator effect - No effect on platelets, GI, renal function
 |  | 
        |  | 
        
        | Term 
 
        | How is cox activity compared with IC50? |  | Definition 
 
        | If you are looking at Cox1/Cox2 - a low ratio tells you the drug is more effective on Cox1 If you are looking at cox2/cox1 - a high number indicates more selective for cox1
 Remember - lower IC50 = less required to take effect.
 |  | 
        |  | 
        
        | Term 
 
        | What effect will different NSAIDs have on platelet aggregation? |  | Definition 
 
        | ASA>Diclofenac>Celebrex/control ASA - irreversible platelet aggregation
 Motrin - reversible
 |  | 
        |  | 
        
        | Term 
 
        | Which NSAID has uricosuric properties? |  | Definition 
 
        | ASA in high doses, but can't use due to gastric side effects. |  | 
        |  | 
        
        | Term 
 
        | How do drugs move to sites of inflammation? |  | Definition 
 
        | The drug is unionized, moves to the site of inflammation and becomes ionized at a basic pH (weak acid) |  | 
        |  | 
        
        | Term 
 
        | Which NSAID produces the highest maximum benefits? Are COX2 inhibitors better than non-selective?
 |  | Definition 
 
        | None of them. They just take different doses to get there. No, best anti-inflammatory effect achieved if you inhibit COX1 and 2
 |  | 
        |  | 
        
        | Term 
 
        | How are ASA and sodium salicylate related? |  | Definition 
 
        | Both act on neutrophils, but sodium salicylate has no effect on COX/platelets |  | 
        |  | 
        
        | Term 
 
        | How does ASA affect NFkB? What other mechanisms are prostaglandin independent?
 |  | Definition 
 
        | Blocks phosphorylation of IkB by IKK --> no transcription ASA also produces lipoxins when inhibiting COX2
 |  | 
        |  | 
        
        | Term 
 
        | What is the main mechanisms of NSAIDs? |  | Definition 
 
        | Inhibits prostaglandins by inhibiting COX enzymes --> less pain from BK, less inflammation Inhibiting prostaglandins also inhibits IL-1 --> fever reduction.
 |  | 
        |  | 
        
        | Term 
 
        | Are selective COX2 inhibitors better analgesics than non-selective? |  | Definition 
 
        | No, but they last longer. |  | 
        |  | 
        
        | Term 
 
        | What are the main side effects of NSAIDs? |  | Definition 
 
        | Increased acid due to PG inhibition - PGs produce bicarb and protect mucous. Renal function - increase in blood pressure, decreased renal perfusion
 Reye's syndrome w/ ASA in children under 18
 |  | 
        |  | 
        
        | Term 
 
        | What are potential drug interactions w/ NSAIDs? |  | Definition 
 
        | - Decrease in RBF interferes w/ loop diuretic activity, which increase PGs. - AceI - builds up BK while NSAIDs reduce BK
 - Hyperkalemia
 |  | 
        |  | 
        
        | Term 
 
        | Which drugs are COX non-specific? |  | Definition 
 
        | ASA Salsalate
 Diflunisal/Dolobid - weak
 Choline Salsalate/Trilisate
 |  | 
        |  | 
        
        | Term 
 
        | Which drugs are Propionic Acids? Non-specific COX inhibitors
 |  | Definition 
 
        | IBU/advil Fenoprofen/Nalfon
 Flurbiprofen/Ansaid - S isomer
 Ketoprofen/Orudis
 Fenoprofen/Nalfon
 Oxaprozin/Daypro
 Naproxen/Aleve
 |  | 
        |  | 
        
        | Term 
 
        | Which drugs are Acetic acids? Non-specific COX inhibitors
 |  | Definition 
 
        | Indomethacin/Indocin - potent Sulindac/Clinoril - prodrug
 Tolmetic/Tolectin
 Nabumetone/Relafen - metabolite
 Diclofenac/Voltaren
 Diclofenac + Misoprostil/Arthrotec
 Ketorolac/Toradol - analgesic only
 |  | 
        |  | 
        
        | Term 
 
        | What drug is a Fenamate? Non-specific COX inhibitor?
 |  | Definition 
 
        | Meclofenamic acid/Meclomen For dysmenorrhea
 |  | 
        |  | 
        
        | Term 
 
        | What drugs are Pyranocarboxylic acids? Non-specific COX inhibitor
 |  | Definition 
 
        | Etodolac/Lodine - may be more selective than mobic Oxicam
 Piroxicam/Feldene
 |  | 
        |  | 
        
        | Term 
 
        | What drug is a Preferential COX2 inhibitor? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What drug is a Cox2 Specific inhibitor? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What drug depletes neuropeptides and how does it work? |  | Definition 
 
        | Zostrix/Capsaicin - works on TRPV-1 receptors. Substance P. Depolarize nerve ending --> release of neuropeptide and eventual depletion --> some pain but then desensitization
 |  | 
        |  | 
        
        | Term 
 
        | What are neutraceuticals? |  | Definition 
 
        | OTCs that are chondroprotective: - Glucosamine - increased GAGs and hyaluronic acid, aggrecan. Inhibits MMPs, IL-1, iNOS
 - Chondroitin - inhibits NFkB, decreases cartilage loss
 Can be equivalent to IBU
 |  | 
        |  | 
        
        | Term 
 
        | Which 3 class of drugs can reduce symptoms in RA? |  | Definition 
 
        | - NSAIDs - DMARDs
 - Steroids
 |  | 
        |  | 
        
        | Term 
 
        | How does NSAID use treat RA? |  | Definition 
 
        | Less PGs, less neutrophils, may have a TNF and IL-1 effect. |  | 
        |  | 
        
        | Term 
 
        | What is an example of a glucocorticoid? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Hypothalamus --> anterior pituitary, ACTH released --> adrenal gland, cortisol released. Cortisol is a negative feedback, controls itself
 |  | 
        |  | 
        
        | Term 
 
        | What is the MOA of steroids? |  | Definition 
 
        | - Genomic theory - enters cytoplasm to produce proteins - Non-genomic theory - binds to cell membranes
 Anti-inflammatory activity tied to glucocorticoid activity
 EITHER NFkB blocked from going into nucleus or block NFkB binding to DNA
 |  | 
        |  | 
        
        | Term 
 
        | What are the physiological effects of steroids? |  | Definition 
 
        | tissue thinning, muscle wasting, diabetes, moon face and buffalo hump. Elevated mood, suppressed immune system Cushing's syndrome
 |  | 
        |  | 
        
        | Term 
 
        | What are sites of action for steroids? |  | Definition 
 
        | - Vascular permeability - Vasodilation
 - Adhesion
 - Chemotaxis
 - Leukocytes
 - Elimination of mediators
 |  | 
        |  | 
        
        | Term 
 
        | How are steroids beneficial? |  | Definition 
 
        | OA - reduce mediators, iNOS, MMPs RA - prevents migration of macrophages and neutrophils into synovial fluid
 SLE - blocks cytokines, reduces antibody complexes
 |  | 
        |  | 
        
        | Term 
 
        | How do you compare steroid potency? |  | Definition 
 
        | Everything is relative to cortisol, so divide mg equivalent by AIF potency = equivalent dose. |  | 
        |  | 
        
        | Term 
 
        | What are the adverse effects of steroid drops? |  | Definition 
 
        | Increase ocular pressure Ocular infections
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Disease modifying anti-rheumatic drugs - Gold/Myochrysine or Solganol
 - Penicillamine/Depen or Cuprimine
 - Hydroxychloroquine/Plaquenil
 - Methotrexate/Rheumatrex
 - Sulfasalazine/Azulfidine
 - Cyclosporine/Sandimmune
 - Minocyline/Minocin
 - Azathoprine/Imuran
 - Leflonomide/Arava
 |  | 
        |  | 
        
        | Term 
 
        | What drugs are in the class of biological agents? |  | Definition 
 
        | - Etanercept/Enbrel - TNF, not antibody - Infliximab/Remicade - TNF
 - Adalimumab/Humira - TNF
 - Anakinra/Kineret - IL-1
 - Rituximab/Rituxan - CD20 on B cells
 - Abatacept/Orencia - B7 on APCs
 - Golimumab/Simponi - TNF
 - Certolizumab pegol/Cimzia - TNF, not an antibody
 - Tocilzumab/Actemra - IL-6
 |  | 
        |  | 
        
        | Term 
 
        | What is the MOA of hydroxychloroquine? |  | Definition 
 
        | Immunomodulator, interferes with antigen processing and the ability to produce antibodies. Concentrates in neutrophils
 Used in RA and SLE. Takes 2-4 months to work.
 |  | 
        |  | 
        
        | Term 
 
        | What is the MOA of sulfasalazine? |  | Definition 
 
        | Sulfa + salacylic acid Decreases antibodies and inhibits T/B cells. Increased formation of adenosine
 works in 1-2 months, not teratogenic
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Decreases T cell activation and RF. Very toxic, takes 6 months to work
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Inhibits DHFR - give folic acid to prevent this. Increased formation of adenosine --> anti-inflammatory. Low dose affects AICAR, inhibits adenosine deaminase, adenosine buildup. Decreased secretion of TNF, IL-1, IL-2, IL-6. Weekly dose, can cause severe fatigue. |  | 
        |  | 
        
        | Term 
 
        | What is the MOA of Leflonamide? |  | Definition 
 
        | Inhibits DHO dehydrogenase, reduces proliferation of T and B cells. Less toxic, still teratogenic. Alternative to MTX. |  | 
        |  | 
        
        | Term 
 
        | What is the MOA of cyclophosphamide? |  | Definition 
 
        | Inhibits mostly B cell activation, some T cells. Immunosuppressive, causes bladder inflammation and pulmonary fibrosis. Last resort. |  | 
        |  | 
        
        | Term 
 
        | What is the MOA of azathioprine? |  | Definition 
 
        | Decreases T and B cell activation - immunosuppressive. A purine antagonist. Bad in gout, some liver toxicity. |  | 
        |  | 
        
        | Term 
 
        | What is the MOA of Mycophenolate? |  | Definition 
 
        | Inhibits the enzyme that makes guanylic acid. Will still have some due to salvage, but lymphocytes have no feedback loop. Overall inhibition of purine synthesis. Similar to AZA in supressing B and T cells |  | 
        |  | 
        
        | Term 
 
        | What is the MOA of cyclosporine? |  | Definition 
 
        | Calcineurin must bind to calmodulin for IL-2 to be produced. Prevents that binding. Don't get the 3rd signal to activate T cells. Gingival hyperplasia |  | 
        |  | 
        
        | Term 
 
        | Which drugs MOA are TNF antagonists? |  | Definition 
 
        | - Etanercept/Enbrel - soluble TNF receptor. Can't use in crohn's. - Infliximab/Remicade - humanized, used IV.
 - Adalimumab/Humira
 - Golimumab/Simponi
 - Certolizumab pegol/Cimzia - pegylated. Decr immunogenicity, longer T1/2. No Fc = no phagocytosis
 |  | 
        |  | 
        
        | Term 
 
        | What is the MoA of Anakinra/Kineret? |  | Definition 
 
        | IL-1 receptor antagonist Should not use in combo with a TNF antagonist due to side effects
 |  | 
        |  | 
        
        | Term 
 
        | What is the MoA of Abatacept/Orencia? |  | Definition 
 
        | CTLA4 + Fc --> competes with CD28 for B7, blocking the 2nd signal in T cell activation |  | 
        |  | 
        
        | Term 
 
        | What is the MoA of Rituxan/Rituximab? |  | Definition 
 
        | Complement mediated cell lysis. Affinity for CD20, activation of complement. MAJOR reactions, can lead to death |  | 
        |  | 
        
        | Term 
 
        | What is the MoA of Tocilzumab/Actemra? |  | Definition 
 
        | IL-6 receptor antagonist. Can be used with MTX |  | 
        |  | 
        
        | Term 
 
        | What is Benlysta/Belimumab? |  | Definition 
 
        | A new drug that targets circulating Blys from B cells, avoiding ADCC. Decreases B cell activation, decreased side effects |  | 
        |  |